Seres Therapeutics
MCRB
80 hedge funds and large institutions have $494M invested in Seres Therapeutics in 2017 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 31 increasing their positions, 15 reducing their positions, and 8 closing their positions.
107% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 15
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
45% more capital invested
Capital invested by funds: $341M → $494M (+$153M)
8% more funds holding
Funds holding: 74 → 80 (+6)
0.06% more ownership
Funds ownership: 3.74% → 3.8% (+0.06%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
80% less call options, than puts
Call options by funds: $1.8M | Put options by funds: $8.84M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$3M |
| 2 |
Renaissance Technologies
New York
|
+$2.09M |
| 3 |
PA
Perceptive Advisors
New York
|
+$1.84M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$1.75M |
| 5 |
JP Morgan Chase
New York
|
+$1.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.8M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$1.57M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$1.41M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.23M |
| 5 |
AG
Artal Group
Luxembourg
|
-$683K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCA
76
Peddock Capital Advisors
Braintree,
Massachusetts
| $5K | – | – | – |
|
77
US Bancorp
Minneapolis,
Minnesota
| $2K | – | – | – |
|
|
HR
78
Howe & Rusling
Rochester,
New York
| $2K | +$1.37K | +5 | New |
|
|
MAM
79
Meeder Asset Management
Dublin,
Ohio
| $1K | -$11.8K | -43 | -96% |
|
|
SQA
80
Simon Quick Advisors
Morristown,
New Jersey
| $1K | +$547 | +2 | New |
|
|
81
Wellington Management Group
Boston,
Massachusetts
| – | -$1.8M | -7,966 | Closed |
|
|
BBA
82
Baker Bros. Advisors
New York
| – | -$1.41M | -6,250 | Closed |
|
83
Citadel Advisors
Miami,
Florida
| – | -$455K | -2,011 | Closed |
|
84
American Century Companies
Kansas City,
Missouri
| – | -$381K | -1,687 | Closed |
|
|
PP
85
PDT Partners
New York
| – | -$288K | -1,275 | Closed |
|
|
HCM
86
Highbridge Capital Management
New York
| – | -$252K | -1,113 | Closed |
|
|
PAM
87
Panagora Asset Management
Boston,
Massachusetts
| – | -$59K | -260 | Closed |
|
|
VWA
88
V Wealth Advisors
Overland Park,
Kansas
| – | -$12K | -55 | Closed |
|
MCRB Hedge Fund Activity: Q3 2017 in Review
80 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q3 2017, worth a combined $494M — up 45% from $341M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new MCRB positions and 8 closed out — a net gain of 6 holders — while 31 added to existing stakes and 15 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $3M. The largest seller was Wellington Management Group, exiting entirely with an estimated $1.8M sold.
- 80 institutional investors held Seres Therapeutics (MCRB) as of Q3 2017, up from 74 in Q2 2017.
- Funds reported $494M of Seres Therapeutics stock for Q3 2017, up 45% quarter-over-quarter.
- 14 funds opened new Seres Therapeutics positions in Q3 2017 and 8 closed out, a net change of +6 holders.
- The largest Seres Therapeutics buyer in Q3 2017 was OrbiMed, an estimated $3M added.
- The largest Seres Therapeutics seller in Q3 2017 was Wellington Management Group, an estimated $1.8M sold.
Based on aggregated 13F filings for Q3 2017.